Información del artículo
El Texto completo está disponible en PDF
Bibliografía General
[ADA, 1997]
ADA.
The Expert Committee on the diagnosis and Classification of Diabetes Mellitus Report ot the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
Diabetes Care, 20 (1997), pp. 1183-1197
[ADA, 1996]
ADA.
The pharmacological treatment of hyperglycemia in NIDDM. Consensus Statements.
Diabetes Care, 19 (1996), pp. 54-61
[ADA, 1998]
ADA.
Drug-Development and drug-approval process. Diabetes Monitor Alberti KGMM Zimmet PZ Definition, diagnosis and classification of diabetes mellitus its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
Diabetic Medicine, 15 (1998), pp. 539-553
[Álvarez Escolá, et.al, 1997]
C. Álvarez Escolá, A. Marco Martínez, M.P. Pérez Unanua, L.F. Pallardo Sánchez.
Agentes insulinosensibilizadories: biguanidas y tiazolidindionas.
Medicine, 64 (1997), pp. 2991-2997
[Boutert, 1998]
K.P. Boutert, J.J.M. Deijns.
Nateglinide (A-4166), a new insulinotrophic agent, controls prandial hyperglycemia in type 2 diabetic patients.
Diabetologia, 41 (1998), pp. 233
[Cheatham, 1998]
W.W. Cheatham.
Repaglinida. Un nuevo agente hipoglicemiante.
Clinical Diabetes, 16 (1998), pp. 70-72
[Day, 1999]
C. Day.
Thiazolidinediones: a new class of antidiabetic drugs.
Diabetic Medicine, 16 (1999), pp. 179-192
[Fernández Fernández, et.al, 1997]
I. Fernández Fernández, C.J. Costa Mestanza, Y. Villafuerte Fernández.
Terapia combinada en la diabetes mellitus tipo 2.
FMC, 10 (1997), pp. 687-695
[Formiguera, 1999]
X. Formiguera.
Tratamiento médico de la obesidad.
Medicina Integral, 33 (1999), pp. 287-304
[Grupo Diabetes SAMFyC, 2000]
Grupo Diabetes SAMFyC.
Tratamiento, (2000),
[Herrera Pombo, 1997]
J.L. Herrera Pombo.
Tratamiento de la diabetes mellitus. Sulfonilureas.
Medicine, 64 (1997), pp. 2984-2990
[Lebovitz, 1999]
H.E. Lebovitz.
Insulin secretagogues: old and new.
Diabetes Reviews, 7 (1999), pp. 139-153
[Lebowitz, 1998]
H.E. Lebowitz.
Fármacos reguladores de la secreción de insulina: sulfonilureas y repaglinida.
Tratamiento de la diabetes mellitus tipo 2 y sus complicaciones (3.a ed.). American Diabetes Association, pp. 127-135
[Lebovitz, et.al, 1998]
H.E. Lebovitz, J. Patel, R. Dole Patwardhan.
Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients.
Diabetologica, 41 (1998),
[Rosenstock, 1996]
J. Rosenstock.
Glimepiride, a new once-daily sulfonylurea.
Diabetes Care, 19 (1996), pp. 1194-1199
[Spencer and Markhan, 1997]
C.M. Spencer, A. Markhan.
Troglitazone.
Drugs, 54 (1997), pp. 89-102
[UK Prospective Diabetes Study Group, 1998]
UK Prospective Diabetes Study Group.
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients whit type 2 diabetes (UKPDS 33).
Lancet, 352 (1998), pp. 837-853
[UK Prospective Diabetes Study Group, 1998]
UK Prospective Diabetes Study Group.
Effect of intensive blood glucose control policy with metformin on complications tin type 2 diabetes patients (UKPDS 34).
Lancet, 352 (1998), pp. 854-865
Copyright © 2000. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
